Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439029 | 0.85 | SMN1; SMN2 (0.54) | PRCPHTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL11469037 | 0.83 | PRCP (0.51) | PRCPHTR2AHTR2CHTR2BSLC6A2 | |
| SCHEMBL11504099 | 0.82 | SLC6A2 (0.42) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL7163573 | 0.78 | SLC5A2 (0.39) | PRCPHTR2AHTR2BSLC6A2SLC6A4 | |
| SCHEMBL6096441 | 0.77 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6TDP1 | |
| SCHEMBL1777 | 0.77 | KDM1A (0.35) | SLC6A4 | |
| SCHEMBL27840083 | 0.77 | FADS1 (0.37) | HTR2AHTR2CHTR2B | |
| SCHEMBL27508666 | 0.76 | SLC5A2 (0.38) | PRCPSMN1; SMN2 | |
| SCHEMBL11503897 | 0.76 | SMN1; SMN2 (0.43) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL11114670 | 0.74 | SMN1; SMN2 (0.37) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411077-B2 | Process for the preparation of a cyano-isobenzofuran | ADORKEN TECHNOLOGY SPA (IT) | 2008-08-12 | — | — | US | disclosed |
| CN-100338051-C | Process for the preparation of citalopram | LUNDHECK AS H (DK) | 2007-09-19 | — | — | CN | disclosed |
| US-20060183925-A1 | Process for the preparation of a cyano-isobenzofuran | ADORKEM TECHNOLOGY SPA | 2006-08-17 | — | — | US | disclosed |
| CN-1258530-C | Crystalline base of citalopram | LUNDBECK & CO AS H (DK) | 2006-06-07 | — | — | CN | disclosed |
| CN-1761658-A | Process for the preparation of a cyano-isobenzofuran | ADORKEM TECHNOLOGY SPA (IT) | 2006-04-19 | — | — | CN | disclosed |
| US-6992198-B2 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2006-01-31 | — | — | US | disclosed |
| EP-1601662-A1 | PROCESS FOR THE PREPARATION OF A CYANO-ISOBENZOFURAN | Adorkem Technology SpA (IT) | 2005-12-07 | — | — | EP | disclosed |
| EP-1601662-A1 | PROCESS FOR THE PREPARATION OF A CYANO-ISOBENZOFURAN | Adorkem Technology SpA (IT) | 2005-12-07 | — | — | EP | disclosed |
| CN-1680350-A | Crystalline base of citalopram | LUNDBECK & CO AS H (DK) | 2005-10-12 | — | — | CN | disclosed |
| US-20040215025-A1 | Method for the preparation of citalopram | H. LUNDBECK A/S (DK) | 2004-10-28 | — | — | US | disclosed |
| WO-1998019511-A3 | METHOD FOR THE PREPARATION OF CITALOPRAM | LUNDBECK & CO AS H (DK) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998019511-A2 | METHOD FOR THE PREPARATION OF CITALOPRAM | H. LUNDBECK A/S (DK) | 1998-05-14 | — | — | WO | disclosed |
| US-5137896-A | Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-08-11 | — | — | US | disclosed |
| US-5057525-A | Stimulators of gastrointestinal motility | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-10-15 | — | — | US | disclosed |
| US-4962115-A | Stimulate motility of gastrointestinal system | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-10-09 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-B1 | NOVEL N-ARYL-PIPERAZINEALKANAMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1987-06-03 | — | — | EP | disclosed |
| EP-0076530-B1 | NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0076530-A2 | Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-04-13 | — | — | EP | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040215025-A1 | Method for the preparation of citalopram | MAOB, HTR1F, MAOA | PRCP 598/4885HTR2A 48/4885HTR2C 39/4885 |
| US-20060183925-A1 | Process for the preparation of a cyano-isobenzofuran | HTR1F, CYP4F12, CYP4F3 | PRCP 1641/4885HTR2A 90/4885HTR2C 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.